Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Torrecillas

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Anticancer Research|October 13, 2012
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapyAndres Garcia Palomo, Iwona Glogowska, Harald Sommer, et al.
European Journal of Oral Implantology|December 14, 2017
Morphological and immunophenotypical differences between chronic periodontitis and peri-implantitis - a cross-sectional studyPablo Galindo-Moreno, Jesús López-Martínez, Mercedes Caba-Molina, et al.
Histology and Histopathology|December 11, 2020
CORRIGENDUM TO: "Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markers"Elena Pozo, Francisco Mesa, Mohamed H Ikram, et al.
Histology and Histopathology|October 3, 2015
Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markersElena Pozo, Francisco Mesa, Mohamed H Ikram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant CapecitabineKarama Asleh, Ana Lluch, Angela Goytain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 19, 2022
Physicians' attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey studyBertha Alejandra Martinez-Cannon, Enrique Soto-Perez-de-Celis, Aura Erazo Valle-Solis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)Ana Lluch, Carlos H Barrios, Laura Torrecillas, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Anticancer Research|October 13, 2012
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapyAndres Garcia Palomo, Iwona Glogowska, Harald Sommer, et al.
European Journal of Oral Implantology|December 14, 2017
Morphological and immunophenotypical differences between chronic periodontitis and peri-implantitis - a cross-sectional studyPablo Galindo-Moreno, Jesús López-Martínez, Mercedes Caba-Molina, et al.
Histology and Histopathology|December 11, 2020
CORRIGENDUM TO: "Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markers"Elena Pozo, Francisco Mesa, Mohamed H Ikram, et al.
Histology and Histopathology|October 3, 2015
Preterm birth and/or low birth weight are associated with periodontal disease and the increased placental immunohistochemical expression of inflammatory markersElena Pozo, Francisco Mesa, Mohamed H Ikram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant CapecitabineKarama Asleh, Ana Lluch, Angela Goytain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 19, 2022
Physicians' attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey studyBertha Alejandra Martinez-Cannon, Enrique Soto-Perez-de-Celis, Aura Erazo Valle-Solis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)Ana Lluch, Carlos H Barrios, Laura Torrecillas, et al.
Pageof 2